Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Spook,are you upset with me over your own behavior ? Do you think others cant read your history of posts and think for them selves.
Look here you are following text book bashing tect." go back to fondling your "top secret information" and stop lying about me " trying to make me out to be the fool,LOL but its no good here spook. Now by the book you should get one of your team members to also post something against me as well. By the Book of course.LOL Spook go back to RB basher land you'll feel better there.LOL
Again spook your question is just one piece of the puzzle. Today its "I want the truth about the Current workforce" next week it will be something else,another piece till you get the picture you want. All to reach your goal.A little bashing carefully placed here and a little there so it dont look like that what your doing. And again here you are using the word "TRUTH" to meat your own ends.Your not after the truth spook your after something else.
Spook, your lead in questions are not designed as a true search for answers but rather to instill and intice people to question anything coming out of Dnap a position of attack that starts out with " I'm asking a Valid question " but to what end ? You have a hidden agenda spook, always trying to lead people into your goal, with suggestive questing.All your posts are that way, just a matter of record. You follow the "Basher Text Book" to the letter including the Team you work with. All your posts are designed to Question the operations and info. from Dnap filled to the brim with subliminal, and implying and insinuating remarks.Always trying to PLANT thoughts in the direction of your goals.Look at the Tect. you used in the first sentence, leading people in your way of thinking; 1} I asked a vaild question; But here we need to know your motive therefore its not vaild till we know what your motive is. 2} no need to be so rude; oh thats good for those who dont already know you and what your up to. 3} I thought this board was DEDICATED to TRUE DD. Here we see you using a double hit Using a truth " the board dedicated to true DD" to support your position. The true Dedication of this board has nothing in common with your real intent. Need i say more.
Spook get a life,please. LOL
Grateful, you forgot nancy and a few others. LOL And dont ask me " WHO " ? There is only so much i can say now about Dnap. To many eyes and ears around and I want to stay in good graces with the right people.
JEG, thanks have a good night. EOM
Going to da Lake have fun everyone.
ann441j, I've been there. I like to hit black jack first make enought to buy into bingo and play for free.LOL
ann441j, Remember the Organ Transplantation deal in 12-01 took 1 year to come to an agreement and begin the work. So they didn't start till 12-02 and end around 12-03.
We will all do very well give it time
And remember even Spock had his Sentimental moments.WHO didn't cry when he said to Jim " I will always be your Friend " !!
Ustacud, Stats and facts do have their place. They are like the foundation and support structure of a house without this cant stand. But what is just as important is the support and value structure shared between us.The simple praise for a job well done or a simple thankyou for your post truns a empty house into a home. They are the flowers and curtains hanging inside that give the house beauty.Stats and Fact,yes very much needed but dont think we can do without this value structure unless you like living in a empty house.Ustacud,i thought your post was very nice, thankyou, you are very much a part of the team.
Again Thank
JEG, it dont all have to be stats and facts you can share here positive things to say to others.Its not all Bus.
Do you recall when Tony was asked how strong financially is Dnap ? His responce was "We are going through a PIPE" and if you recall Tony said "no big buys for the rest of the year" as per the wall street Transcript july 28,2003
stakddek, no problem anytime.
MJAM,sorry,Doubloon is not to be trusted. I have knowed him for the last 3 years and he has a history of lieing on the RB board about Gmed. He once worked for the comp. long ago. and left very unhappy. Do not trust him. He lied about the listing to the otb and major discoveries soon to come and many other things about Gmed.
It looks like Lonnie Bookbinder PH.D worked at RIBI Immunochem it also looks like Corixa wanted to buy out RIBI at one time but RIBI turned them down.
Heres a little info. on RIBI -
Ribi ImmunoChem Research, Inc. develops biopharmaceutical products that stimulate the immune system to generate natural agents and signals to prevent and treat human diseases. The company researches, develops, produces and markets these products some of which are under investigation by other companies for use as adjuvants. The company also manufactures clinical products and develops processes for the commercial scale production of its compounds. The company's technology is based on potent capacities of certain microbial products to modulate the cytokine cascade in man and other animals. The product development of the company is the use of MPL immunomodulator in combination with other immunomodulator. The company's product, human biopharmaceutical is being regulated by the FDA, which requires to be tested for the use of human treatment. The company has 20 research products to date. The company has been using its research products to develop immunotherapeutic agents for the treatment of malignant tumors and other diseases. The company has spent approximately $237,000 towards year 2000 expenses. Contracts & licences accounted for 53% of 1998 revenues & biopharmaceutical products, 47%.
Special from Lonnie Bookbinder, PhD, MBA to RIBI shareholders at www.rsvc.org
The author of these observations has a thirty-year career in biopharmaceuticals and worked for RIBI from 1994-1997.
As most are aware, the majority of RIBI sales are derived from MPL and other adjuvants, which are refined as a part of a modified bacteria causing a cascading effect of immune responses. RIBI adjuvants, especially MPL, are considered valuable and useful in many different vaccine candidates.
Importantly, to expand the base of knowledge, RIBI scientists initiated research to develop a synthetic adjuvant and have been successful. They have discovered, synthesized, tested and patented a next generation of super adjuvants. Think of these discoveries as a valuable franchise for the future of immunology. RIBI publications note that RIBI's second generation adjuvant technology platform is based on novel AGP- aminoalkyl glucosamine phosphate- adjuvants. These new synthetic compounds display potent bioactivity, possess an excellent safety profile and are amenable to alternative methods for vaccine delivery, such as intranasal delivery. Synthetic AGP compounds also may prove advantageous in ease of formulation, manufacturing scale-up and simplified quality assurance. In the hands of RIBI scientists, AGP's have been successfully used in pre-clinical testing of tetanus, hepatitis and influenza vaccines. RIBI scientists and managers confirm the worth of the AGP product derivatives and vaccine producers want it. There is a very significant potential value in AGP for RIBI.
This writer believes that RIBI is a treasure trove of potential and actual lines of research and that RIBI stock is worth much more than $2.00 per share. This writer believes that the RIBI Shareholder Value Committee suggestions represent the best way to realize the longterm value of RIBI Shares. Defeat of the Corixa offer is the first step in the right direction. Eighteen years of RIBI employees' scientific research and development deserves to be fully exploited. A sell out merger at $2.00 per share should be unsatisfactory to independent RIBI shareholders.
On Matthew J. Thomas - The company is also pleased to announce that Matthew J. Thomas, Ph.D. will be joining the company as a Scientist from his post at the H. Lee Moffit Cancer Center, University of South Florida, Tampa, FL. Dr. Thomas obtained his Ph.D. in Biology from the Department of Biology and Institute of Molecular Biology, University of Oregon. He is the recipient of the competitive Leukemia Society of America Fellowship, and has published original molecular biology research in such prestigious journals as Cell, Oncogene, Gene and Nucleic Acids Research. The addition of Dr. Thomas will help increase the Companies data flow and analysis."
From the Leukemia and Lymphoma Society 2001 Annual Report: Research Grant recipient Matthew J.Thomas, PhD –1999 University of South Florida.
Yiwen He, Michael K Armanious, Matthew J Thomas & W Douglas Cress. Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene 13 July 2000, Volume 19, Number 30.
Matthew J. Thomas, Angelina A. Platas, and Diane K. Hawley. Transcriptional Fidelity and Proofreading by RNA Polymerase II. Cell May 15, 1998: 93 (4).
Matthew J. Thomas, Edward Seto. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene Volume 236, Issue 2, Page 197-355 (20 August 1999).
Funded Projects 2001
Grant Number: 001/2001
PI Name: Mirhashemi, Ramin and Arena, J. Fernando
Project Title: Pharmacogenomics Approach to Predict Chemotherapeutic Response to Ovarian Cancer Treatment.
Abstract: DESCRIPTION: (Adapted from investigator's abstract)
The goal of this project is to identify, qualify and quantify the genetic and environmental determinants of human variability in Ovarian Cancer chemotherapy response. To do this, we will explore the connection between human genetic variation (polymorphism), extrinsic factors (environment) and treatment response (phenotype) using state-of-the-art automated genomics equipment and genetic algorithms. Specifically, we will build a relational database containing patient genotype, phenotype and environmental data in order to "mine" statistically relevant associations and patterns using novel mathematical techniques. The specific drugs whose efficacy we will investigate are Adriamycin, Taxol, Topotecan and Thalidomide.
Of the many steps we will take in this project, the first is to identify novel SNP/Haplotypes for genes of suspected import to Ovarian Cancer chemotherapy. These genes include xenobiotic metabolism and basic cellular housekeeping genes such as tubulins and topoisomerases. For novel SNP/Haplotype discovery, we will use a relatively small (approx. 50) patient cohort. Entire regions of genes will be sequenced for these patients, and new SNPs discovered by comparing the sequences. New haplotypes for these SNPs and genes in the population will be documented. The genes that we will perform this for genes whose known functionality lend them as good candidates as modulators of chemotherapeutic drug efficacy. This particular phase of the study will address inadequacies with the current public human genome variation database (dbSNP). Since the public databaese relies on limited numbers of donors, who are generally healthy, it is necessarily biased against causative or etiologically relevant variants for most human afflictions. We will also mine the public human genome databases for known and undiscovered SNPs. All data mining for new SNPs will utilize a proprietary data mining software package developed at DNAprint genomics. The database of SNP locations and Haplotypes that results will contribute to a sort of "road map" which offers the opportunity to gain unique and valuable insight into Ovarian Cancer. This "road map" will serve as a guide by which the high-throughput experiments will be conducted.
The second step in our project will be to score these novel SNPs and Haplotypes in large patient cohorts. We will use the "road map" of SNP/HAP variability data with a larger study cohort (several hundreds of patients) to score genotypes in several hundred genes. SNPs and haplotypes will be scored using an automated genotyping platform and proprietary inferential informatics.
In addition to genotypes, matching biographical information such as drug dosage, response, environmental and other information will be collected and added to the relational database. This database will then be mined for associations using various mathematical techniques that consider sources of pattern on multiple levels of genetic complexity. Methodology types that will be used include geometric modeling, bayesian clustering, and artificial intelligence such as neural networks. Methodologies will incorporate various encoding schemes and genetic parameters, produced from the application of proprietary genetic algorithms and genetic grouping variables. Haplotype and sub-haplotype patterns will be investigated using pair-wise linkage disequilibria. New methods for improving the detection power for three-way and even four-way linkage disequilibria will be explored. Haplotypes will be inferred from genotype data. If successful, the project will culminate in the publication, patenting and commercialization of our results, which may eventually lead to a new diagnomics product that can be used with personal genetic information to guide patient chemotherapy treatment decisions.
Institution: UNIVERSITY OF MIAMI
1475 N. W. 12TH AVE.
MIAMI, FL 33136
Fiscal Year: 2001
Department: OB/GYN
Project Start: 01-January, 2001
Project End: 31-December, 2002
FUNDING AGENCY DNA PRINT GENOMICS
Address: DNAPrint genomics, Inc.900 Cocoanut Ave.Sarasota, FL 34236941-366-3400941-952-9770 fax
Grant Number: 002/2001
PI Name: Arena, J. Fernando
Project Title: Development of a BRCA1 and BRCA2 mutation screening assay for women of African descent.
Abstract: DESCRIPTION: (Adapted from investigator's abstract)
The long term objective of this application is to develop and to clinically validate a screening panel for specific BRCA1 and BRCA2 mutation/genetic variants in women of African descent with breast cancer. The development of such panel will allow its incorporation into clinical practice with clear improvement of genetic counseling for this minority population. African-American women under age 50 in the United States have the highest rate of new cases of breast cancer in the nation. In addition, African-American women of all ages have a larger percentage of poorly differentiated breast cancer, that is more likely to occur at an earlier age and to be estrogen and progesterone receptor negative - all factors associated with more aggressive tumorgenicity. Based on this preliminary data and a thorough review of all published English literature, we have identified thirteen mutations and thirteen unclassified variants in BRCA1 and six mutations and ten variants in BRCA2. A screening panel for such BRCA1 and BRCA2 mutations/variants will be designed to develop an efficient assay for eventual use in clinical practice. This assay is based on a combination of multiplex PCR and multiplex SSCP in order to provide a high throughput screening method for the above designated genetic alterations. SSCP variants will be further investigated by DNA sequencing to confirm the exact genetic change. The development of this screening panel will have an important impact on genetic counseling for women of African descent. It may also be helpful in anticipating the design of preventive strategies (mammography, chemoprevention, or prophylactic surgery) and in selecting appropriate therapeutic protocols for this underserved and under investigated patient population.
Institution: UNIVERSITY OF MIAMI
1475 N. W. 12TH AVE.
MIAMI, FL 33136
Fiscal Year: 2001
Department: OB/GYN
Project Start: 01-January, 2002
Project End: 31-December, 2003
FUNDING AGENCY Sylvester Comprehensive Cancer Center
Address: 1475 N.W. 12th Miami Fl, 33136
davia,generate,generate the power of togeatherness lets get Tony so freaken high on Pos. thinking he's good to go for another 10 Million snips.LOL
artforlife,LOL ya,thats a good one. Pos. thinking and prayer how can we lose.
RA,RA,RA Gooooo Dnap - Goooooooo Dnap
Buy Dnap. Get in now before its to late.LOL
Do you want to live the easy life ?
Do you want lots of money ?
Do you want to be rich ?
You Cant go wrong Buy Today DNAP
The very best in investment DNAP
Go Dnap Go !!!!
Only 4 Mo's to go and 2004 is here. Min. 4 more Press releases, Max. 6 what could they be about ? LOL We have had a press release every mo. since Nov. 2001.
Dont worry were going to get there. Have faith,when you have doubt fill that space with a good book or review some of the filings or better yet read the news letter.This will make you feel better.
We going to the moon - http://community.mikebonnell.com/gallery/showphoto.php?photo=455&size=big
Here are some of Dnap's products;
Forensics DNA Classifiers:
Retinome {sm}- shade of eye color
Retinome {tm}- Genetic eye color classifier
Retinome {tm-ha} Hair color classifier
DNAWitness suit classifier
Skin Tone- Pending status
Height and weight classifier in pending status
Ancestrybydna 2.0 classifier - for continental affiliation
Ancestrybydna 3.0 classifier - for ethnic affiliation
Statnome classifier - info. can be found on their web and newsletter.
Ovarian Classifier - info. can be found on their web and their newsletter.
ADMIXMAP - A whole new Genome Screening Platform that is combined w/ other compositions and NEW highly Specialized Analytical Alogorithms.
University of Miami/ Jackson Memorial Medical center - Breast Cancer project due to end by 2003.
NYS Mary Lee Johnson Richards Organ Transplantation center - project to come to its end 2003.
And so much more !!!!
Matching Dna With Transplantation Patients- Were all going to be RICH,RICH,RICH
"Tony inedicated it took one year just to come to a working agreement,that puts us at Nov,2002. A 1 year term puts it at Nov.,2003 completed".
In November 2001, NYU's Mary Lea Johnson Richards Organ Transplantation Center agreed to provide us with informed consent qualified patient specimens and matching clinical data. We will genetically screen the specimens for markers
and/or marker sets that can be used to distinguish between drug responders and non-responders. To do this, we will employ proprietary genotyping protocols, data resources (the PHENOME SNP database) and our informatics platform. The goal of the project is to identify pharmacogenomic classifiers that could be used to match renal transplantation patients with the optimal immunosuppressant for their genetic architecture. We expect the project to take about one year to complete, and we expect the results to extend to patients for a wide range of transplantation procedures. The Mary Lea Johnson Richards Organ Transplantation Center is one of the busiest and most successful transplant programs in the United States
Dnap and BREAST CANCER - WOW - we going to the moon
Grant Number: 002/2001 BREAST CANCER - WOW - Testing ends 2003 see below.
PI Name: Arena, J. Fernando - Scientific Advisor to Dnap
Project Title: Development of a BRCA1 and BRCA2 mutation screening assay for women of African descent.
Abstract: DESCRIPTION: (Adapted from investigator's abstract)
The long term objective of this application is to develop and to clinically validate a screening panel for specific BRCA1 and BRCA2 mutation/genetic variants in women of African descent with breast cancer. The development of such panel will allow its incorporation into clinical practice with clear improvement of genetic counseling for this minority population. African-American women under age 50 in the United States have the highest rate of new cases of breast cancer in the nation. In addition, African-American women of all ages have a larger percentage of poorly differentiated breast cancer, that is more likely to occur at an earlier age and to be estrogen and progesterone receptor negative - all factors associated with more aggressive tumorgenicity. Based on this preliminary data and a thorough review of all published English literature, we have identified thirteen mutations and thirteen unclassified variants in BRCA1 and six mutations and ten variants in BRCA2. A screening panel for such BRCA1 and BRCA2 mutations/variants will be designed to develop an efficient assay for eventual use in clinical practice. This assay is based on a combination of multiplex PCR and multiplex SSCP in order to provide a high throughput screening method for the above designated genetic alterations. SSCP variants will be further investigated by DNA sequencing to confirm the exact genetic change. The development of this screening panel will have an important impact on genetic counseling for women of African descent. It may also be helpful in anticipating the design of preventive strategies (mammography, chemoprevention, or prophylactic surgery) and in selecting appropriate therapeutic protocols for this underserved and under investigated patient population.
Institution: UNIVERSITY OF MIAMI
1475 N. W. 12TH AVE.
MIAMI, FL 33136
Fiscal Year: 2001
Department: OB/GYN
Project Start: 01-January, 2002
Project End: 31-December, 2003
FUNDING AGENCY Sylvester Comprehensive Cancer Center
Address: 1475 N.W. 12th Miami Fl, 33136
Dnap's Statnome info. -
From 10Ksb 4-15-2003
Statnome. Statnome is the product we are developing in conjunction with a group of Jacksonville physicians to classify patients as adverse responders or good responders to a class of drugs called statins. Hypercholesterolemic and dyslipidemic patients are at increased risk for heart disease. Currently, these patients are prescribed medications, nicknamed "statins," to reduce this risk.Statins function to decrease cholesterol levels by inhibiting a key enzyme in the cholesterol pathway. According to the National Heart, Lung, and Blood Institute's National Cholesterol Education Program,
high cholesterol is one of the key risk factors for heart disease.
Heart disease is the leading cause of death for both men and women in the United States, and more than 90 million American adults, or about 50 percent of the population, have elevated blood cholesterol levels.
A study published in the New England Journal of Medicine in September 1998 says heart disease deaths have declined steadily over the last 30 years, decreasing by 10.3 percent between 1990 and 1994 alone. This
improvement is largely attributable to better prevention of heart disease through the widespread use of statins.
Notwithstanding the efficacy of this class of drugs, individual patients respond differently to statins. About 2-5% of patients are discontinued from statin treatment due to adverse experiences including hepatocellular toxicity (indicated by elevated serum levels of certain liver enzymes), and more rarely, acute renal failure. In
fact, it is recommended that physicians monitor this toxicity by performing liver function tests prior to, and at 12 weeks following,both the initiation of therapy and any elevation of dose, and periodically thereafter. As a recent Time magazine article points out,statins may potentially serve as a useful preventative tool to reduce
the risk of heart disease in the general, healthy population. A key impediment for the expansion of the statin market in this way is the danger posed by adverse events associated with use of these drugs. For example, the long-term effects of hepatocellular injury are not
clearly understood.
The Statnome product(s) could help reduce the risk associated with the use of statins in the general population. The Company expects its Statin project to result in several "diagnomics" test solutions for
routine patient pre-screening prior to statin prescription. Based on the prevalence of dyslipidemia and hypercholesteremia in the population, such a product could enjoy entry into a market in excess of several billion dollars (drug sales). At present our scientists have completed the screen of the xenobiotic genome for the Statnome project and are validating the performance of the resulting classifier.
***************************************************************************************
10k;
At present our scientists have completed the screen of the xenobiotic genome for the Statnome project and are validating the performance of the resulting classifier.
...and this:
Thus, the Company has scaled back its sample collection efforts and is focusing on validating its Statin prediction product (STATNOME) and building a market for and completing its DNA Witness 2.0 line of forensic products. Pending the acquisition of investment funding or the realization of profits from product sales, DNAPrint intends to resume previous rates of collection for its various developmental stage pharmacogenomics projects.
*************************************************************************************************
From the first Newsletter:
OTHER TESTS - We have finished both the genotyping and the computational screening for Lipitor and Zocor, and we have finished the genotyping but not the computational screening for about 15 other drugs we have good sample sizes for. As we complete these projects, we will disclose the results within a formal, peer-reviewed setting such as a professional meeting or in the scientific literature.
*************************************************************************************************
Sept. 23, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP - News) announced on Friday successful results from its ongoing research into the genetic basis for variable Statin response. The results were presented to an audience of health care professionals at the 7th Annual Disease Management Congress in Chicago, IL.
CEO Dr. Tony Frudakis described Company research that has resulted in the identification of certain gene variants associated with and predictive for Statin response. Statins are a class of drugs used to treat lipid disorders and reduce the risk of cardiovascular disease. Largely due to patient genetics, about 25% of patients fail to respond positively to any given Statin, but those that fail to respond to one often respond to another. The findings are the result of a two-year study that focused on 575 patients and seven different clinical measures of response. Using proprietary screening methods, Company scientists were able to identify an unexpectedly large number of variants linked to response. Those associated with response to standard doses of Artorvastatin (sold under the trade name Lipitor by Pfizer, NYSE:PFE) were generally different from those associated with response to standard doses of Simvistatin (sold under the trade name Zocor by Merck, NYSE:MRK), and those predictive for efficacy (how well the drug does its job) were different from those predictive of adverse events such as early stage hepatocellular toxicity (liver stress) or myalgia (muscle pain). The research condensed mathematical encodings for these variants, which the Company calls "eigengenotypes", into a complex genetics classifier capable of explaining almost all of the observed variability in response. Details on how the "eigengenotypes" were measured and computed, or from what genes they are derived were not presented.
The results were described as the fabric for a new genomics test, called STATNOME(TM), which the Company intends to market to the managed health care industry. By allowing physicians to match patients with the Statin most appropriate for their genetic constitution, STATNOME(TM) could enable a dramatic enhancement the therapeutic benefit of this class of drugs. The Company hopes that STATNOME(TM) will reduce the need for frequent follow up visits to the doctors office, obviate an entire menu of clinical tests for monitoring Statin response and reduce the waste that comes from giving medicines to people who are genetically incapable of responding to them. In so doing, the new test could help managed care providers save thousands of dollars per patient, while at the same time, treat their patients more effectively.
Until the tests are manufactured and distributed, Dr. Frudakis explained that the Company plans to exclusively provide STATNOME(TM) classification services for early clinical adopters and progressive patients. The commencement of this service would be announced at a later date. He also outlined Company plans to begin offering services based on the OVANOME(TM) test, which was introduced by the Company last year as the world's first genomics-based test for flagging patients who are incompatible with paclataxel and carboplatin combination chemotherapy (which is the current FDA approved first-line therapy for ovarian cancer; paclitaxel is sold under the trade name Taxol and carboplatin is sold under the trade name Paraplatin, both are manufactured by Bristol-Myers Squibb, NYSE:BMY). The commencement of STATNOME(TM) and OVANOME(TM) services would make DNAPrint the only laboratory in the world using internally-developed, wholly owned and drug-specific classifiers for the individualization of drug treatment. The tests would be among the very first genomics-based tests ever applied before routine drug use, or for any other clinical practice.
The STATNOME(TM) test could have significant implications for the safety and effectiveness of Artorvastatin and Simvistatin, which combine to serve a $12 billion annual market projected to grow to $20 billion by 2003. Though generally well tolerated, adverse events associated with the use of Statins have recently begun to receive widespread attention. Recently Bayer (NYSE:BAY - News) was forced to pull their Statin "Baycol" from the market due to a fatal response linked to muscle damage and myalgia. Though myalgia is reversible, like hepatocellular toxicity, it is part of a continuum of pathology that leads physicians to switch treatments. By flagging the genetically incompatible before treatment, the Company hopes that STATNOME(TM) will help minimize the negative impact of this widely used class of drugs and change the "trial and error" mentality of today's drug prescription process. In addition, STATNOME(TM) could help expand the market for Statins, many of which are already considered "blockbuster" drugs. For example, Statins are usually given to patients that have a lipid condition that can lead to cardiovascular disease, but there are an estimated 30 million healthy people in the US who are at risk of developing this condition for whom Statins would serve as an effective prophylactic. Mainly due to side effects, and the cost of monitoring these side effects, the cost/impact and risk/reward values for a healthy person at risk of developing a lipid disorder is less desirable than that for the already afflicted. As a result, Statins are still not used in the healthy population. By accurately flagging those who would develop an adverse reaction to them before the drug is given, STATNOME(TM) could someday help Statins overcome this barrier for more widespread use.
*************************************************************************************************Some of the Statinome drugs DNAP is reviewing...01-01-02
Baycol........>now banned by the FDA for high risks involved.
Lescol
Lipitor
Lopid
Mevacor
Niacin
Niaspan
Pravachol
Zocor
http://www.dnaprint.com/bioform.pdf
*************************************************************************************************
From the shareholders meeting March, 2003 -Reported by worktoplay - post# 232636
Ovanome is about a year from market, and DNAP anticipates marketing through a partner. I asked if Statnome was similarly a year out, and the response surprised me. Tony indicated that Statnome would be marketed sooner and the marketing would be handled by DNAP. Obviously, the company is anticipating a much larger market for the Statin classifers which would make it cost effective to run the samples on the UHT.
*************************************************************************************************
DNAPrint may also participate in the pharmaceutical company expansion into genomics by partnering its ADMIXMAP platform, and/or sharing with the pharmaceutical industry new drug targets/indications that are discovered in house. DNAPrint also expects to enter into collaborations with leading pharmaceutical companies to conduct pre-clinical pharmacogenomics research on new drugs in their pipelines.
The next market for genomics-based products is DNAPrint's pharmacogenomics market. This market is also known as the "personalization of medicine" market, part of the molecular diagnostics market identified above. DNAP's product
pipeline includes OVANOME, STATNOME, and others that classify a patient's genetic characteristics and their potential response to drugs. DNAPrint may also participate in the pharmaceutical company expansion into genomics by partnering its ADMIXMAP platform, and/or sharing with the pharmaceutical industry new drug targets/indications that are discovered in house. DNAPrint also expects to enter into collaborations with leading pharmaceutical companies to conduct pre-clinical pharmacogenomics research on new drugs in their pipelines.
From - 10ksb filing date 4-15-03
Part 1
overview of the Market
# 14
Clinical Genotyping requires regulatory compliance any new drugs would be subject to FDA approved phase 1 testing.I dont think anything would be started without the FDA involved and that would be NEWS. I think my conjecture is Tony already has a App. submitted on a Patent for a NEW DRUG in the works,informal testing has taken place with stunning results and Now headed for the "fast Tract" the FDA process will begin in 2004. As this is progressing Drugs already approved {statnome, Ovarian} will hit the Head Lines most likely in 2004 and by the time the smoke clears we will have New Drugs.